Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.52 |
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16454838 | 0.85 | F2 (0.55) | ESR1ESR2PTGS2KIF11KDM4E | |
| SCHEMBL17919578 | 0.84 | ESR1 (0.49) | ESR1ESR2PTGS2KIF11KDM4E | |
| SCHEMBL2289172 | 0.83 | KIF11 (0.61) | ESR1ESR2PTGS2KIF11KDM4E | |
| SCHEMBL22599752 | 0.80 | KIF11 (0.56) | ESR1ESR2PTGS2KIF11 | |
| SCHEMBL7076291 | 0.78 | ESR1 (0.71) | ESR1ESR2PTGS2KIF11MAPK14 | |
| SCHEMBL15563263 | 0.78 | PTGS2 (0.72) | ESR1ESR2PTGS2KDM4EMEN1 | |
| SCHEMBL4816763 | 0.78 | PTGS2 (0.74) | ESR1ESR2PTGS2KDM4EMEN1 | |
| SCHEMBL18552201 | 0.77 | ESR1 (0.69) | ESR1ESR2PTGS2MAPK14 | |
| SCHEMBL18552154 | 0.77 | ESR1 (0.69) | ESR1ESR2PTGS2MAPK14 | |
| SCHEMBL18610257 | 0.76 | ESR1 (0.73) | ESR1ESR2PTGS2MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030559-B1 | URAZOLE COMPOUNDS | UNIV GENT (BE) | 2017-06-28 | — | — | EP | disclosed |
| US-9586935-B2 | Urazole compounds | UNIVERSITEIT GENT (BE) | 2017-03-07 | — | — | US | disclosed |
| US-9586935-B2 | Urazole compounds | UNIVERSITEIT GENT (BE) | 2017-03-07 | — | — | US | disclosed |
| US-20160200707-A1 | URAZOLE COMPOUNDS | UNIVERSITEIT GENT (BE) | 2016-07-14 | — | — | US | disclosed |
| US-20160200707-A1 | URAZOLE COMPOUNDS | UNIVERSITEIT GENT (BE) | 2016-07-14 | — | — | US | disclosed |
| WO-2015018928-A1 | URAZOLE COMPOUNDS | UNIVERSITEIT GENT (BE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200707-A1 | URAZOLE COMPOUNDS | UFL1, UFM1, SULT1E1 | ESR1 791/4885ESR2 1322/4885PTGS2 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.